Specialty: Mental Health, Primary sub-specialty: Psychosis - schizophrenia
Conditions
Interventions
After baseline assessments have been completed, participants will be randomly allocated to either one of two groups by the Clinical Trials Unit at King's College London using block randomisation.
Int
Sponsors
Surrey and Borders Partnership NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosis of schizophrenia, and be experiencing current distressing persecutory delusions (assessed using the PSYRATS) 2. Stable on psychiatric medication for at least three months prior to the consent meeting 3. No plans for changes to psychiatric medication during the course of the study 4. Not received psychological therapy in the past three months or to have any plans for psychological therapy during the course of the study 5. Aged over 18 years of age 6. Able to provide informed consent to take part
Exclusion criteria
Exclusion criteria: 1. Participants will not have an identified organic cause for their symptoms 2. Diagnosis of a learning disability. 3. Participants with a significant risk of violence to others.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measures as of 24/05/2018: 1. Depression is measured using Beck Depression Inventory II (Beck et al, 1996) at baseline and 12 weeks 2. Psychotic symptoms are measured using the Psychotic Symptoms Rating Scale (PSYRATS): Delusions subscale at baseline and 12 weeks Previous primary outcome measures: 1. Depression is measured using Beck Depression Inventory II (Beck et al, 1996) at baseline and 12 weeks 2. Recruitment rate is recorded as the number of participants consented to the study per research assistant days, measured at trial end 3. Retention rate is recorded as the number of participants contributing to all data collection points (providing full baseline and post-group data) at 12 weeks. The number of participants classified as completers (attended at least 6 mindfulness sessions) will also be reported | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 24/05/2018: 1. Recruitment rate is recorded as the number of participants consented to the study per research assistant days, measured at trial end. 2. Retention rate is recorded as the number of participants contributing to all data collection points (providing full baseline and post-group data) at 12 weeks. The number of participants classified as completers (attended at least 6 mindfulness sessions) will also be reported Previous secondary outcome measures: 1. Quality of Life is measured using the World Health Organisation Quality of Life-Bref (WHOQOL-BREF) at baseline and 12 weeks 2. Psychotic symptoms are measured using the Psychotic Symptoms Rating Scale (PSYRATS): Delusions subscale at baseline and 12 weeks 3. Progress towards recovery is measured by The Choice of outcome in CBT for Psychosis (CHOICE) at baseline and 12 weeks | — |
Countries
United Kingdom
Contacts
Public ContactEryna Tarant
Outcome results
None listed